There are likely to be confounding molecular factors affecting sensitivity and resistance in cancer cells and in addition the effects of PI3K inhibitors on processes such as angiogenesis and the tumour microenvironment are also likely to be important and contribute to therapeutic activity. The gene discussed is PIK3CA; the disease is cancer.